Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 18/20 | 0.62 |
| ▸ | MMP2 | P08253 | 12/20 | 0.62 |
| ▸ | MMP14 | P50281 | 4/20 | 0.62 |
| ▸ | MMP9 | P14780 | 4/20 | 0.62 |
| ▸ | MMP3 | P08254 | 3/20 | 0.62 |
| ▸ | MMP8 | P22894 | 3/20 | 0.62 |
| ▸ | MMP12 | P39900 | 3/20 | 0.62 |
| ▸ | MMP16 | P51512 | 2/20 | 0.62 |
| ▸ | MMP1 | P03956 | 7/20 | 0.56 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.53 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.53 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898955 | 0.87 | MMP9 (0.62) | MMP13MMP2MMP14MMP9MMP3 | |
| SCHEMBL8364832 | 0.80 | SMN1; SMN2 (0.44) | MMP13MMP2MMP14MMP9MMP3 | |
| SCHEMBL8364949 | 0.75 | MMP2 (0.50) | MMP13MMP2MMP14MMP9MMP3 | |
| SCHEMBL5898975 | 0.75 | MMP2 (0.64) | MMP13MMP2MMP14MMP9MMP3 | |
| SCHEMBL5919644 | 0.75 | MMP1 (0.74) | MMP13MMP2MMP14MMP9MMP3 | |
| SCHEMBL4912518 | 0.72 | ALDH1A1 (0.53) | MMP2 | |
| SCHEMBL26133998 | 0.70 | MMP2 (0.52) | MMP13MMP2MMP14MMP9MMP3 | |
| SCHEMBL6764872 | 0.70 | MMP13 (0.70) | MMP13MMP2MMP14MMP9MMP3 | |
| SCHEMBL6764875 | 0.70 | MMP13 (0.70) | MMP13MMP2MMP14MMP9MMP3 | |
| SCHEMBL6764610 | 0.70 | MMP13 (0.70) | MMP13MMP2MMP14MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115632-B1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | G. D. SEARLE & CO. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050075374-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | PHARMACIA CORPORATION | 2005-04-07 | — | — | US | disclosed |
| US-6794511-B2 | AN ENZYME INHIBITORS OF METALLOPROTEASE; TREATING CONNECTIVE TISSUE DEGRADATION CAUSED BY INFLAMMATION OR TUMOR | G. D. SEARLE | 2004-09-21 | — | — | US | disclosed |
| EP-1406602-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406626-A2 | SULPHONYL ARYL HYDROXAMATES AND THEIR USE AS MMP INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6696449-B2 | CONTROL DEGRADATION OF CONENCTING TISSUE; CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6683078-B2 | REDUCING DEGRADATION OF CONNECTIVE TISSUE DUE TO CANCER OR INFLAMMATION | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6656954-B2 | Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity | PHARMACIA CORPORATION | 2003-12-02 | — | — | US | disclosed |
| EP-0973392-B1 | SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | MONSANTO CO (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | PHARMACIA CORPORATION | 2003-09-11 | — | — | US | disclosed |
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003007930-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| US-20020103239-A1 | Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds | BEDELL LOUIS J (US) | 2002-08-01 | — | — | US | disclosed |
| US-6380258-B2 | METALLOPROTEASE INHIBITOR | G. D. SEARLE, L.L.C. | 2002-04-30 | — | — | US | disclosed |
| WO-2001085680-A2 | SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORPORATION (US) | 2001-11-15 | — | — | WO | disclosed |
| US-20010020021-A1 | SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | G.D. SEARLE & CO. | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020021-A1 | SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | MMP2, MMP1, MMP3 | MMP13 6/4885MMP2 1/4885MMP14 11/4885 |
| US-20050075374-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | MMP1, MMP2, MMP3 | MMP13 5/4885MMP2 2/4885MMP14 12/4885 |
| US-20020103239-A1 | Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds | MMP2, MMP1, MMP3 | MMP13 6/4885MMP2 1/4885MMP14 11/4885 |
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | ARSA, MMP1, MMP3 | MMP13 8/4885MMP2 7/4885MMP14 12/4885 |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | ARSA, AADAC, ASPH | MMP13 26/4885MMP2 27/4885MMP14 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.